Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys.

Journal article

We examined the ability of the antiparkinsonian agent (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) to enter the systemic circulation in therapeutic concentrations after continuous transdermal absorption in squirrel monkeys rendered parkinsonian by MPTP. Direct subcutaneous administration of (+)-PHNO in the dose range of 2.5 to 20 micrograms/kg restored locomotor activity to levels seen in normal monkeys for approximately 1 hour. Application of transdermal patches capable of delivering, into an infinite sink, an estimated 2.6 micrograms/cm2/h of (+)-PHNO over a skin surface area of 4.78 to 19.12 cm2 also restored locomotor activity to the normal range during a 24-hour period. We suggest the use of transdermal application of PHNO as a novel drug delivery system for the improved management of Parkinson's disease.

Authors: Rupniak, N; Tye, S; Jennings, C; Loper, A; Bondi, J

• Publication status: Published
• Journal: Neurology
• Volume: 39
• Issue: 3
• Pages: 329-335
• Publication date: 1989-03-01
• DOI: 10.1212/wnl.39.3.329
• EISSN: 1526-632X
• ISSN: 0028-3878
• Language: English
• Keywords: Saimiri; Parkinson Disease, Secondary; Antiparkinson Agents; Pyridines; Oxazines; Behavior, Animal; Animals; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Male; Administration, Cutaneous